As pharmaceutical manufacturers seek novel solutions for challenging conditions, cannabinoids—especially cannabidiol (CBD)—are emerging as promising candidates for drug innovation. With favorable regulatory developments and increasing scientific evidence supporting their potential in treating central nervous system disorders, pain, and cancer, cannabinoids are set to expand therapeutic possibilities. This whitepaper explores the latest research on cannabinoids and highlights how dsm-firmenich is partnering with the pharmaceutical industry to drive early-stage drug development in this exciting field. Download to learn more about advancing cannabinoid-based therapies.
Discover how pharmaceutical quality management is advancing through proactive strategies that reduce risk, improve visibility, and support compliance.
Discover how dsm-firmenich and Bayer reduced vitamin C’s carbon footprint by 49% through renewable energy, process innovation, and sustainable pharma collaboration.
Discover how dsm-firmenich is tackling the challenge of bitter medicine with a receptor-based technology designed to elevate drug palatability and improve patient adherence.
Have an idea for a new project, a groundbreaking innovation, or a need for expert services? Let’s talk.
Don’t just take our word for it. Discover how our solutions can support your product development journey.
Customized blends of functional ingredients in one single, efficient premix.
Streamline your product development process and get to market faster.
From trade shows to conferences and other industry events, find out where you can meet us next.
Talking Nutrition, Health & Care
Explore new science, consumer insights, industry news and more in our latest articles.
Discover educational whitepapers, webinars, publications and technical information.
Request samples, place orders and view product documentation.